Form 4: Core Laboratories Director Michael Straughen Reports Stock Transactions
SEC Filing
Director Michael Straughen reports the disposition and acquisition of Core Laboratories Inc. common stock on April 1, 2025, according to a Form 4 filing.
Summary
- Michael Straughen, a director of Core Laboratories Inc., filed a Form 4 with the SEC.
- The report details transactions involving Core Laboratories Inc. common stock on April 1, 2025.
- Straughen disposed of 4,634 shares of common stock at a price of $14.98.
- He also acquired 9,317 shares of common stock at $0.
- Following these transactions, Straughen beneficially owns 29,186 shares of common stock.
- The acquisition of 9,317 shares is related to the vesting of restricted shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company directors and officers.
Stakeholder Impact
- The transactions may provide insights to shareholders regarding the director's view on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of stock transactions (disposal and acquisition) and vesting of restricted shares. |
| 04/02/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Core Laboratories Inc., Stock Transaction, Beneficial Ownership, Michael Straughen, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.